Formulation and Pathohistological Study of Mizolastine–Solid Lipid Nanoparticles–Loaded Ocular Hydrogels
Ghada Ahmed El-Emam,1 Germeen NS Girgis,1 Mohammed Fawzy Hamed,2 Osama Abd El-Azeem Soliman,1 Abd El Gawad H Abd El Gawad1 1Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt; 2Department of Pathology, Faculty of Veterinary Medicine, Mansoura University, Ma...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/804dfc1ef5b94be6a692d201b4d448f9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:804dfc1ef5b94be6a692d201b4d448f9 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:804dfc1ef5b94be6a692d201b4d448f92021-12-02T19:49:53ZFormulation and Pathohistological Study of Mizolastine–Solid Lipid Nanoparticles–Loaded Ocular Hydrogels1178-2013https://doaj.org/article/804dfc1ef5b94be6a692d201b4d448f92021-11-01T00:00:00Zhttps://www.dovepress.com/formulation-and-pathohistological-study-of-mizolastinesolid-lipid-nano-peer-reviewed-fulltext-article-IJNhttps://doaj.org/toc/1178-2013Ghada Ahmed El-Emam,1 Germeen NS Girgis,1 Mohammed Fawzy Hamed,2 Osama Abd El-Azeem Soliman,1 Abd El Gawad H Abd El Gawad1 1Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt; 2Department of Pathology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, EgyptCorrespondence: Ghada Ahmed El-EmamDepartment of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, EgyptTel +20 10-9059-0989Email ghadaelemam26@yahoo.comBackground: Mizolastine (MZL) is a dual-action nonsedating topical antihistamine anti-inflammatory agent that is used to relieve allergic conditions, such as rhinitis and conjunctivitis. Solid lipid nanoparticles (SLNs) are advanced delivery system in ophthalmology, with the merits of increasing the corneal drug absorption and hence improved bioavailability with the objective of ocular drug targeting.Methods: First, MZL was formulated as MZL-SLNs by hot homogenization/ultrasonication adopting a 32 full factorial design. Solid-state characterization, in vitro release, and stability studies have been performed. Then, the optimized MZL-SLNs formula has been incorporated into ocular hydrogels using 1.5% w/v Na alginate and 5% w/v polyvinylpyrrolidone K90. The gels were evaluated via in vitro release as well as in vivo studies by applying allergic conjunctivitis congestion in a rabbit-eye model.Results: The optimized formula (F4) was characterized by the highest entrapment efficiency (86.5± 1.47%), the smallest mean particle size (202.3± 13.59 nm), and reasonable zeta potential (− 22.03± 3.65 mV). Solid-state characterization of the encapsulation of MZL in SLNs was undertaken. In vitro results showed a sustained release profile from MZL-SLNs up to 30 hours with a non-Fickian Higuchi kinetic model. Stability studies confirmed immutability of freeze-dried MZL-SLNs (F4) upon storage for 6 months. Finally, hydrogel formulations containing MZL-SLNs, proved ocular congestion disappearance with completely repaired conjunctiva after 24 hours. Moreover, pretreatment with MZL-SLNs–loaded hydrogel imparted markedly decreased TNF-α and VEGF-expression levels in rabbits conjunctivae compared with post-treatment with the same formula.Conclusion: MZL-SLNs could be considered a promising stable sustained-release nanoparticulate system for preparing ocular hydrogel as effective antiallergy ocular delivery systems.Keywords: mizolastine, solid lipid nanoparticles, 32 full factorial design, sustained release, in vivo studyEl-Emam GAGirgis GNSHamed MFEl-Azeem Soliman OAAbd El Gawad AEGHDove Medical Pressarticlemizolastinesolid lipid nanoparticles32 full factorial designsustained releaseand in-vivo study.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 7775-7799 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
mizolastine solid lipid nanoparticles 32 full factorial design sustained release and in-vivo study. Medicine (General) R5-920 |
| spellingShingle |
mizolastine solid lipid nanoparticles 32 full factorial design sustained release and in-vivo study. Medicine (General) R5-920 El-Emam GA Girgis GNS Hamed MF El-Azeem Soliman OA Abd El Gawad AEGH Formulation and Pathohistological Study of Mizolastine–Solid Lipid Nanoparticles–Loaded Ocular Hydrogels |
| description |
Ghada Ahmed El-Emam,1 Germeen NS Girgis,1 Mohammed Fawzy Hamed,2 Osama Abd El-Azeem Soliman,1 Abd El Gawad H Abd El Gawad1 1Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt; 2Department of Pathology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, EgyptCorrespondence: Ghada Ahmed El-EmamDepartment of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, EgyptTel +20 10-9059-0989Email ghadaelemam26@yahoo.comBackground: Mizolastine (MZL) is a dual-action nonsedating topical antihistamine anti-inflammatory agent that is used to relieve allergic conditions, such as rhinitis and conjunctivitis. Solid lipid nanoparticles (SLNs) are advanced delivery system in ophthalmology, with the merits of increasing the corneal drug absorption and hence improved bioavailability with the objective of ocular drug targeting.Methods: First, MZL was formulated as MZL-SLNs by hot homogenization/ultrasonication adopting a 32 full factorial design. Solid-state characterization, in vitro release, and stability studies have been performed. Then, the optimized MZL-SLNs formula has been incorporated into ocular hydrogels using 1.5% w/v Na alginate and 5% w/v polyvinylpyrrolidone K90. The gels were evaluated via in vitro release as well as in vivo studies by applying allergic conjunctivitis congestion in a rabbit-eye model.Results: The optimized formula (F4) was characterized by the highest entrapment efficiency (86.5± 1.47%), the smallest mean particle size (202.3± 13.59 nm), and reasonable zeta potential (− 22.03± 3.65 mV). Solid-state characterization of the encapsulation of MZL in SLNs was undertaken. In vitro results showed a sustained release profile from MZL-SLNs up to 30 hours with a non-Fickian Higuchi kinetic model. Stability studies confirmed immutability of freeze-dried MZL-SLNs (F4) upon storage for 6 months. Finally, hydrogel formulations containing MZL-SLNs, proved ocular congestion disappearance with completely repaired conjunctiva after 24 hours. Moreover, pretreatment with MZL-SLNs–loaded hydrogel imparted markedly decreased TNF-α and VEGF-expression levels in rabbits conjunctivae compared with post-treatment with the same formula.Conclusion: MZL-SLNs could be considered a promising stable sustained-release nanoparticulate system for preparing ocular hydrogel as effective antiallergy ocular delivery systems.Keywords: mizolastine, solid lipid nanoparticles, 32 full factorial design, sustained release, in vivo study |
| format |
article |
| author |
El-Emam GA Girgis GNS Hamed MF El-Azeem Soliman OA Abd El Gawad AEGH |
| author_facet |
El-Emam GA Girgis GNS Hamed MF El-Azeem Soliman OA Abd El Gawad AEGH |
| author_sort |
El-Emam GA |
| title |
Formulation and Pathohistological Study of Mizolastine–Solid Lipid Nanoparticles–Loaded Ocular Hydrogels |
| title_short |
Formulation and Pathohistological Study of Mizolastine–Solid Lipid Nanoparticles–Loaded Ocular Hydrogels |
| title_full |
Formulation and Pathohistological Study of Mizolastine–Solid Lipid Nanoparticles–Loaded Ocular Hydrogels |
| title_fullStr |
Formulation and Pathohistological Study of Mizolastine–Solid Lipid Nanoparticles–Loaded Ocular Hydrogels |
| title_full_unstemmed |
Formulation and Pathohistological Study of Mizolastine–Solid Lipid Nanoparticles–Loaded Ocular Hydrogels |
| title_sort |
formulation and pathohistological study of mizolastine–solid lipid nanoparticles–loaded ocular hydrogels |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/804dfc1ef5b94be6a692d201b4d448f9 |
| work_keys_str_mv |
AT elemamga formulationandpathohistologicalstudyofmizolastinendashsolidlipidnanoparticlesndashloadedocularhydrogels AT girgisgns formulationandpathohistologicalstudyofmizolastinendashsolidlipidnanoparticlesndashloadedocularhydrogels AT hamedmf formulationandpathohistologicalstudyofmizolastinendashsolidlipidnanoparticlesndashloadedocularhydrogels AT elazeemsolimanoa formulationandpathohistologicalstudyofmizolastinendashsolidlipidnanoparticlesndashloadedocularhydrogels AT abdelgawadaegh formulationandpathohistologicalstudyofmizolastinendashsolidlipidnanoparticlesndashloadedocularhydrogels |
| _version_ |
1718375969935327232 |